Table 1.
Patient characteristics.
| Conditioning regimens | p valuea | ||||
|---|---|---|---|---|---|
|
|
|
||||
| Covariate | Statistics | Level | BU/CY N = 73 | FLU/MEL N = 83 | |
| Sex | N (Col %) | Female | 42 (57.53) | 38 (45.78) | .156 |
| N (Col %) | Male | 31 (42.47) | 45 (54.22) | ||
| Status | N (Col %) | CR1 | 36 (49.32) | 36 (43.37) | .424 |
| N (Col %) | CR2 | 12 (16.44) | 12 (14.46) | ||
| N (Col %) | All others | 25 (34.24) | 35 (42.17) | ||
| Cytogenetic classification | N (Col %) | Favorable | 7 (10) | 4 (5) | .246 |
| N (Col %) | Intermediate | 44 (62.86) | 43 (53.75) | ||
| N (Col %) | Poor | 19 (27.14) | 33 (41.25) | ||
| Extramedullary disease | N (Col %) | No | 68 (93.15) | 73 (87.95) | .119 |
| N (Col %) | Yes | 5 (6.85) | 10 (12.05) | ||
| KPSa | N (Col %) | Low (<80) | 23 (35.38) | 31 (38.75) | .537 |
| N (Col %) | High (80+) | 42 (64.62) | 49 (61.25) | ||
| Transplant type | N (Col %) | MRD | 27 (36.98) | 28 (33.73) | .376 |
| N (Col %) | MUD | 46 (63.02) | 55 (66.27) | ||
| HLA disparity | N (Col %) | 0 | 62 (84.93) | 64 (77.11) | .271 |
| N (Col %) | 1–2 | 11 (15.07) | 19 (22.89) | ||
| Graft source | N (Col %) | BM | 11 (15.07) | 13 (15.66) | .621 |
| N (Col %) | PBSC | 62 (84.93) | 70 (84.34) | ||
| Year of transplant | N (Col %) | 2005–2009 | 51 (69.86) | 27 (32.53) | <.001 |
| N (Col %) | 2010–2014 | 22 (30.14) | 56 (67.47) | ||
| Age at transplant | N | 73 | 83 | <.001 | |
| Mean | 39.32 | 56.99 | |||
| Median | 39.1 | 59 | |||
| CD34 dosea | N | 72 | 83 | .435 | |
| Mean | 11.55 | 10.35 | |||
| Median | 10.31 | 9.78 | |||
The p value is calculated by ANOVA for numerical covariates; and chi-square test or Fisher's exact for categorical covariates, where appropriate. BU: busul-fan; CY: cyclophosphasmide; FLU: fludarabine; MEL: melphalan; KPS: Karnofsky performance status; HLA: human leukocyte antigen.
Bold values represent variables reaching statistical significance with p value < .05.
a
Data were not available for CD34 dose in 1/73 BuCy patient; KPS for 8/73 Bu/Cy and 3/83 Flu/Mel patients; and cytogenetics in 1/73 Bu/Cy and 3/83 Flu/Mel patients.